Joined: 12/6/2011
Posts: 3326
|
From Alzheimer's Daily News:
(Source: Clinical Psychiatry News ) - Results from new studies of the investigational imaging agents florbetaben and flutemetamol indicate that they may help to support a diagnosis of Alzheimer's disease or rule it out, with the potential to improve both clinical management and research.
Comparisons of the radioactive imaging agents showed that the compounds have high sensitivity and specificity for detecting the presence of beta-amyloid plaques.
With a half-life of 10 hours, florbetaben could be much more clinically useful than the first amyloid imaging agent developed, Pittsburgh Compound B, which has a 20-minute half-life, making it much more difficult to obtain quality images in anything but a research setting.
Two separate studies of flutemetamol suggest that the drug not only binds strongly to beta-amyloid plaques, but that such binding also correlates with cognitive status.
Go to full story: http://www.clinicalpsychiatrynews.com
|